• About us
• Contact

Advertisement

Organisation › Details

Mage Biologics Inc.

Mage Biologics is a special purpose company created to develop a novel, orally administered monoclonal antibody to clinical proof of concept for the treatment of ulcerative colitis. Mage Biologics is jointly funded by TVM Life Science Innovation II and Tillotts Pharma and is led by an experienced management team. *

 

	Start	2023-07-20 established jv
	Industry	humanised mAb targeting UC (Mage Biologics / Tillotts Pharma / Numab Therapeutics)
	Industry 2	oral drug delivery technology for biologics
	Person	Spleiss, Johannes (Zeria 202307 Head Scientific Affairs Tillotts Pharma + 202307– CEO of Mage Biologics)
	Person 2	Miklosi, Chantal (Mage Biologics 202307– CFO)
	Region	United States (USA)_oo
	Country	United States (USA)
	City	n. a.
		Address record changed: 2023-07-31
Basic data	Employees	n. a.
		* Document for »About Section«: Tillotts Pharma AG. (7/20/23). "Press Release: Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis". Montréal, Munich & Rheinfelden.
		Record changed: 2024-01-30

Advertisement

More documents for Mage Biologics Inc.

• [1] Tillotts Pharma AG. (7/20/23). "Press Release: Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis". Montréal, Munich & Rheinfelden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.